News | October 13, 2025
Cadila launches allergy relief tablet Dlorfast-M
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
Cadila Pharmaceuticals has introduced Dlorfast-M-Tablets as a dual-action therapy that targets two key pathways of allergic response
ExellenS applies optimized facility designs, equipment, and processes across all sites to ensure equivalency and speed
Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases
Merck will showcase results in innovative solutions in HIV treatment and prevention
Several technologies for hemoglobinopathies are being transferred to commercial partners
New gene expression profiling test enhances precision in assessing lung transplant rejection and injury
The new line features advanced isolator technology to deliver enhanced sterility assurance, throughput and operational precision
The company plans to use the funds raised from the net proceeds to repay or prepay certain loans
New filling line approval supports delivery of integrated, end-to-end solutions across the entire biologics and bioconjugates value chain
Lilly's Omvoh is the first and only IL-23p19 antagonist to show four years of sustained, corticosteroid-free comprehensive patient outcomes in ulcerative colitis
Subscribe To Our Newsletter & Stay Updated
